Bill > HB2922

This bill modifies provisions related to alternative therapies by establishing a framework for "eligible patients" to access "investigational drugs, biological products, or devices" that have completed phase one of clinical trials but are not yet approved by the U.S. Food and Drug Administration (FDA). An eligible patient is defined as someone with a terminal, life-threatening, or severely debilitating condition or illness who has exhausted other FDA-approved treatment options and relevant clinical trials in the state, and has received a physician's recommendation for such an investigational treatment. The patient, or their guardian, must provide written informed consent, and their physician must document their eligibility. The bill clarifies that manufacturers can make these treatments available, either for free or by charging for manufacturing costs, but are not required to do so. It also specifies that health care insurers and the department of corrections are not mandated to cover these costs, though they may choose to do so. Importantly, the bill protects physicians from losing their licenses or facing disciplinary action solely for recommending these investigational treatments to eligible patients, and prohibits action against a healthcare provider's Medicare certification for the same reason, except in cases of gross negligence or willful misconduct. The bill also outlines conditions for offering the drug if a clinical trial is closed due to lack of efficacy or toxicity, and requires notification of safety information from clinical trials.

https://house.mo.gov/Bill.aspx?bill=HB2922&year=2026&code=R